407,663 Shares in DexCom, Inc. $DXCM Bought by DSM Capital Partners LLC

Key Points

• DSM Capital Partners LLC made a new investment in DexCom, Inc., acquiring 407,663 shares valued at approximately $27.84 million, positioning DexCom as its 27th largest holding.
• Several hedge funds have increased their positions in DexCom, with Russell Investments Group Ltd. raising its holdings by 63.7% in the first quarter.
• Analysts show a positive outlook for DexCom, with 16 analysts assigning a buy rating and an average price target of $99.89, following the company's earnings report that exceeded expectations.

DSM Capital Partners LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 407,663 shares of the medical device company's stock, valued at approximately $27,839,000. DexCom makes up approximately 0.5% of DSM Capital Partners LLC's holdings, making the stock its 27th biggest position. DSM Capital Partners LLC owned about 0.10% of DexCom at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Golden State Wealth Management LLC lifted its position in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares during the period. Private Trust Co. NA boosted its stake in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after buying an additional 335 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of DexCom by 29.3% in the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after acquiring an additional 702 shares during the period. Dynamic Advisor Solutions LLC increased its position in DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after acquiring an additional 1,333 shares during the last quarter. Finally, Stonebridge Financial Group LLC lifted its holdings in DexCom by 944.5% in the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after acquiring an additional 2,909 shares during the period. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director owned 56,621 shares in the company, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director owned 33,411 shares of the company's stock, valued at $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 31,906 shares of company stock valued at $2,675,251. 0.32% of the stock is owned by company insiders.

DexCom Price Performance

DXCM traded down $0.1420 during trading on Tuesday, hitting $80.6780. 605,543 shares of the company traded hands, compared to its average volume of 3,872,602. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a market cap of $31.64 billion, a PE ratio of 56.00, a P/E/G ratio of 1.70 and a beta of 1.43. The stock's 50-day simple moving average is $82.96 and its two-hundred day simple moving average is $79.95. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. During the same period in the previous year, the firm posted $0.43 earnings per share. The business's revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Raymond James Financial upped their price target on shares of DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 31st. William Blair raised shares of DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Barclays boosted their price objective on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Piper Sandler raised their target price on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Finally, Morgan Stanley lifted their target price on DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and an average target price of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.